3.81  0.12 (3.25%)		09-13 16:00
Open: 3.75 High: 3.91 Volume: 129,780		Pre. Close: 3.69 Low: 3.73 Market Cap: 182(M)

Short term
Mid term
Targets	6-month :	4.6	1-year :	5.37
Resists	First :	3.94	Second :	4.6
Pivot price	3.59
Supports	First :	3.32	Second :	2.95
MAs	MA(5) :	3.74	MA(20) :	3.53
	MA(100) :	5.61	MA(250) :	5.82
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	71.4	D(3) :	74.9
RSI	RSI(14): 55.2
52-week	High :	11.76	Low :	1.33

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ STTK ] has closed below upper band by 7.5%. Bollinger Bands are 77.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.91 - 3.93	3.93 - 3.95
Low:	3.69 - 3.71	3.71 - 3.73
Close:	3.78 - 3.81	3.81 - 3.84

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Tue, 27 Aug 2024
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga

Thu, 08 Aug 2024
Shattuck Labs, Inc.'s (NASDAQ:STTK) institutional investors lost 24% last week but have benefitted from longer-term gains - Simply Wall St

Wed, 10 Jul 2024
Kymera Therapeutics Surges 23.4%: Is This an Indication of Further Gains? - Markets Insider

Sat, 15 Jun 2024
Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation - Simply Wall St

Fri, 14 Jun 2024
Shattuck Labs Reports Promising Cancer Trial Outcomes - TipRanks

Fri, 14 Jun 2024
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	48 (M)
Held by Insiders	2.767e+007 (%)
Held by Institutions	13.3 (%)
Shares Short	3,750 (K)
Shares Short P.Month	0 (K)

EPS	-8.632e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	427.1 %
Return on Equity (ttm)	-39.8 %
Qtrly Rev. Growth	4.12e+006 %
Gross Profit (p.s.)	402.57
Sales Per Share	-39.14
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-63 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.1
Price to Cash Flow	2.87

Dividend	0
Forward Dividend	5.31e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.